Dr. Chi Chi, the lead author of the article entitled, “HOXD-AS1 Exerts Oncogenic Functions and Promotes Chemoresistance in Cisplatin-Resistant Cervical Cancer Cells” (by Chi Chi, Min Mao, Zongji Shen, Youguo Chen, Jie Chen, and Wenjie Hou, Hum Gene Ther 2018;29(12):1438–1448; doi: 10.1089/hum.2017.256) requested that their published article in Human Gene Therapy be officially retracted due to their recent inability to repeat the results of the experiments in the study.
An email from Dr. Chi received by the editorial office read, “My co-authors and I recently repeated the experiments and found some differences compared to the previous study results, which drew our great attention. For the rigor of scientific research, we have to [retract] our manuscript and need more time to verify the final results. We [are] sorry for this decision…”
After reviewing the circumstances and seeking all authors' agreement, the editorial leadership of the journal agreed to retract the article.
Human Gene Therapy
is committed to upholding the rigorous standards of scientific publishing and the veracity of the literature.
Get full access to this article
View all access options for this article.
References
1.
TorreLA, BrayF, SiegelRL, et al.Global cancer statistics, 2012. CA Cancer J Clin, 2015; 65:87–108.
2.
JingL, YuanW, RuofanD, et al.HOTAIR enhanced aggressive biological behaviors and induced radio-resistance via inhibiting p21 in cervical cancer. Tumour Biol, 2015; 36:3611–3619.
3.
SakuragiN. Refining insight into cervical cancer progression. Lancet Oncol, 2014; 15:371–372.
4.
Martens-UzunovaES, BöttcherR, CroceCM, et al.Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol, 2014; 65:1140–1151.
5.
ZhangY, DunY, ZhouS, et al.LncRNA HOXD-AS1 promotes epithelial ovarian cancer cells proliferation and invasion by targeting miR-133a-3p and activating Wnt/beta-catenin signaling pathway. Biomed Pharmacother, 2017; 96:1216–1221.
6.
LuS, ZhouJ, SunY, et al.The noncoding RNA HOXD-AS1 is a critical regulator of the metastasis and apoptosis phenotype in human hepatocellular carcinoma. Mol Cancer, 2017; 16:125.
7.
ZhengL, ChenJ, ZhouZ, et al.Knockdown of long non-coding RNA HOXD-AS1 inhibits gastric cancer cell growth via inactivating the JAK2/STAT3 pathway. Tumour Biol, 2017; 39:1010428317705335.
8.
ZhangY, DunY, ZhouS, et al.LncRNA HOXD-AS1 promotes epithelial ovarian cancer cells proliferation and invasion by targeting miR-133a-3p and activating Wnt/beta-catenin signaling pathway. Biomed Pharmacother, 2017; 96:1216–1221.
9.
PicklesK, CarterSM, RychetnikL, et al.Doctors' perspectives on PSA testing illuminate established differences in prostate cancer screening rates between Australia and the UK: a qualitative study. BMJ Open, 2016; 6:e011932.
10.
GrizzleWE. Missed opportunities and lost lives: Consequences of some proposed changes to regulations on research with human tissues—Letter. Clin Cancer Res, 2015; 21:5404–5405.
11.
DrakeBF, BrownK, McGowanLD, et al.Secondary consent to biospecimen use in a prostate cancer biorepository. BMC Res Notes, 2016; 9:346.
12.
BiL, MaF, TianR, et al.AJUBA increases the cisplatin resistance through hippo pathway in cervical cancer. Gene, 2018; 644:148–154.
13.
XiongY, SunF, DongP, et al.iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling. J Exp Clin Cancer Res, 2017; 36:48.
14.
TaoT, YangX, QinQ, et al.NHERF1 enhances cisplatin sensitivity in human cervical cancer cells. Int J Mol Sci, 2017; 18.
15.
MarkmanM. Advances in cervical cancer pharmacotherapies. Expert Rev Clin Pharmacol, 2014; 7:219–223.
16.
PectasidesD, KamposiorasK, PapaxoinisG, et al.Chemotherapy for recurrent cervical cancer. Cancer Treat Rev, 2008; 34:603–613.
17.
PontingCP, BelgardTG. Transcribed dark matter: Meaning or myth?. Hum Mol Genet, 2010; 19:R162–168.
18.
MattickJS. The genetic signatures of noncoding RNAs. PLoS Genet, 2009; 5:e1000459.
19.
GuttmanM, AmitI, GarberM, et al.Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature, 2009; 458:223–227.
20.
GibbEA, BrownCJ, LamWL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer, 2011; 10:38.
21.
MercerTR, DingerME, MattickJS. Long non-coding RNAs: insights into functions. Nat Rev Genet, 2009; 10:155–159.
22.
ZhuangYT, XuDY, WangGY, et al.IL-6 induced lncRNA MALAT1 enhances TNF-alpha expression in LPS-induced septic cardiomyocytes via activation of SAA3. Eur Rev Med Pharmacol Sci, 2017; 21:302–309.
23.
TangJ, LiY, SangY, et al.LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling. Oncogene, 2018; doi: 10.1038/s41388-018-0310-4.
24.
FanH, LvP, MuT, et al.LncRNA n335586/miR-924/CKMT1A axis contributes to cell migration and invasion in hepatocellular carcinoma cells. Cancer Lett, 2018; 429:89–99.
25.
WangY, ZengX, WangN, et al.Long noncoding RNA DANCR, working as a competitive endogenous RNA, promotes ROCK1-mediated proliferation and metastasis via decoying of miR-335-5p and miR-1972 in osteosarcoma. Mol Cancer, 2018; 17:89.
26.
LiangY, SongX, LiY, et al.A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer. Cell Death Dis, 2018; 9:563.
27.
XiaoZ, QuZ, ChenZ, et al.LncRNA HOTAIR is a prognostic biomarker for the proliferation and chemoresistance of colorectal cancer via MiR-203a-3p-mediated Wnt/ss-Catenin signaling pathway. Cell Physiol Biochem, 2018; 46:1275–1285.
28.
XueD, LuH, XuHY, et al.Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12. J Cell Mol Med, 2018; 22:3223–3237.
29.
CaiT, LiuY, XiaoJ. Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma. Cancer Med, 2018; 7:1404–1415.
30.
LiuS, LeiH, LuoF, et al.The effect of lncRNA HOTAIR on chemoresistance of ovarian cancer through regulation of HOXA7. Biol Chem, 2018; 399:485–497.
31.
ZhenQ, GaoLN, WangRF, et al.LncRNA PCAT-1 promotes tumour growth and chemoresistance of oesophageal cancer to cisplatin. Cell Biochem Funct, 2018; 36:27–33.
32.
ShenCJ, ChengYM, WangCL. LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells. J Drug Target, 2017; 25:637–644.
33.
FengY, ZouW, HuC, et al.Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin. Arch Biochem Biophys, 2017; 623–624:20–30.
34.
WangQ, JiangS, SongA, et al.HOXD-AS1 functions as an oncogenic ceRNA to promote NSCLC cell progression by sequestering miR-147a. Onco Targets Ther, 2017; 10:4753–4763.
35.
WangH, HuoX, YangXR, et al.STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Cancer, 2017; 16:136.
36.
LiX, ZhaoX, YangB, et al.Long non-coding RNA HOXD-AS1 promotes tumor progression and predicts poor prognosis in colorectal cancer. Int J Oncol, 2018; 53:21–32.
37.
XuY, ZhangG, ZouC, et al.LncRNA MT1JP suppresses gastric cancer cell proliferation and migration through MT1JP/MiR-214-3p/RUNX3 axis. Cell Physiol Biochem, 2018; 46:2445–2459.
38.
LiD, YangM, LiaoA, et al.Linc00483 as ceRNA regulates proliferation and apoptosis through activating MAPKs in gastric cancer. J Cell Mol Med, 2018; doi: 10.1111/jcmm.13661
39.
ZhangG, LiS, LuJ, et al.LncRNA MT1JP functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer. Mol Cancer, 2018; 17:87.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
